What you should know:
1. For the fourth quarter, Pacira reported $122.4 million in revenues.
2. Exparel, Pacira’s flagship drug, drove fourth-quarter and full-year sales, posting $116.9 million and $407.9 million, respectively.
3. The company posted a net loss on the quarter and year of $4.9 million and $11 million, respectively.
4. Pacira issued its 2020 outlook, predicting full-year revenues between $485 million and $500 million.
Pacira CEO David Stack said: “Demand has continued to mount within the anesthesia community as Exparel-based nerve and field blocks take hold as institutional protocol. Additionally, we enhanced our non-opioid pain management product portfolio with the addition of iovera and we are seeing great interest from the marketplace around this innovative system.”
More articles on surgery centers:
PE-backed Prism Vision snags Maryland eye group — 4 insights
Florida ASC buyer projects $18M profit in 1st year: 5 details
Physician-owned eye group acquires California practice
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
